Saturday February 16, 2019

Exercise may help Patients with advanced Gastrointestinal Cancer to cope better with side effects of Chemotherapy

The findings showed that as a result of the exercise, muscle mass improved as did functional properties, such as balance, walking speed and leg strength

0
//
Exercise, Pixabay

London, March 12, 2017: Walking or jogging either three times a week for 50 minutes or five times a week for 30 minutes may help patients with advanced gastrointestinal cancer to cope better with the side effects of chemotherapy, a study has showed.

Side effects of the chemotherapy may include loss of sensation, weakness, exhaustion, infections or severe diarrhoea, which often causes patients to reduce or even discontinue the programme.

NewsGram brings to you current foreign news from all over the world.

The findings showed that as a result of the exercise, muscle mass improved as did functional properties, such as balance, walking speed and leg strength.

Further, the toxicity of the chemotherapy could be reduced through moderate activity.

“This is important because it is especially due to severe toxic effects that patients with gastrointestinal cancer often have to reduce the dose or even discontinue the chemotherapy altogether,” Katrin Stucher, doctoral student at the Goethe University Frankfurt in Germany, said in a statement.

Check out NewsGram for latest international news updates.

Patients, who were engaged in exercise along with chemotherapy could tolerate the therapy better and experience less disease recurrence (relapses) later on.

“We believe that it will make sense in future to offer patients opportunities for physical exercise during chemotherapy. To eliminate adversities through the weather, exercise rooms could be set up in hospitals,” Stucher added. (IANS)

Next Story

Study Reveals Shorter Duration of Radiation Safe in Treating Prostate Cancer

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested.

0
cancer
The study showed that this type of radiation - stereotactic body radiotherapy - is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run. Pixabay

Men with low or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment, according to researchers including one of Indian-origin.

The study showed that this type of radiation – stereotactic body radiotherapy – is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run.

“Most men with low or intermediate-risk prostate cancer undergo conventional radiation, which requires them to come in daily for treatment and takes an average of nine weeks to complete,” said lead author Amar Kishan, Assistant Professor at University of California, Los Angeles, in the US.

smoking
Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease. Pixabay

“With the improvements being made to modern technology, we have found that using stereotactic body radiotherapy, which has a higher dose of radiation, can safely and effectively be done in a much shorter timeframe without additional toxicity or compromising any chance of a cure,” said Kishan.

For the study, the team included 2,142 men with low or intermediate-risk prostate cancer who were treated with stereotactic body radiotherapy. They were followed for a median of 6.9 years.

Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease.

cancer
These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease. Pixabay

In addition, the recurrence rate for men with low-risk disease was 4.5 per cent, 8.6 per cent for the less aggressive intermediate-risk, and 14.9 per cent for the more aggressive intermediate-risk group, findings published in the journal JAMA Network Open showed.

Overall, the recurrence rate for intermediate-risk disease was 10.2 per cent.

Also Read: Facebook to Come up with ‘Unsend’ Feature on Messenger

These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease.

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested. (IANS)